Valuable researchers have delivered promising results from the INTEGRATE IIa Phase III trial, evaluating regorafenib, an oral multikinase inhibitor, in patients with refractory advanced gastric and esophagogastric junction cancer (AGOC).
This double-blind, placebo-controlled trial enrolled 251 participants globally, comparing regorafenib with placebo alongside best supportive care. The results are encouraging:
- Overall Survival (OS): Regorafenib significantly improved OS with a hazard ratio (HR) of 0.68, increasing median OS to 4.5 months compared to 4.0 months with placebo.
- 12-Month Survival Rates: 19% for regorafenib vs. 6% for placebo, indicating prolonged survival benefits
- Progression-Free Survival (PFS): HR of 0.53, showing regorafenib effectively delays disease progression.
- Quality of Life (QoL): Demonstrated delayed deterioration in global QoL (HR 0.68), maintaining patient well-being during treatment.
- The safety profile aligns with previous studies, reaffirming regorafenib’s tolerability.
These findings highlight regorafenib’s potential as a valuable treatment option for patients with limited therapeutic alternatives in refractory AGOC.
